Program
linerixibat
Also written as “Linerixibat”, “GSK2330672” and “GSK2330672 (linerixibat)”.
Its studies are mostly in Pruritus · Diabetes Mellitus, Type 2 · Liver Cirrhosis, Biliary · Cholestasis, led by GlaxoSmithKline.
Furthest: phase 3, since Nov 15, 201914 company-led studies, 2 open or runningNext primary completion: Oct 23, 2028 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKline | 142 open or running | phase 3since Nov 15, 2019 | Jun 16, 2011 | Oct 23, 2028phase 3 · NCT07860710 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 16, 2011First study: phase 1 study in Diabetes Mellitus, Type 2First studyNCT01416324 · 17 enrolled · United States
- May 17, 2012Phase 1 study in Diabetes Mellitus, Type 2NCT01607385 · 56 enrolled · United States
- Jul 3, 2013Phase 2 study in Cholestasis, IntrahepaticNCT01899703 · 22 enrolled · United Kingdom
- Aug 22, 2013Phase 2 study in Diabetes Mellitus, Type 2NCT01929863 · 16 enrolled · United States
- Jul 24, 2014Phase 2 study in Diabetes Mellitus, Type 2NCT02202161 · 70 enrolled · United States
- Nov 15, 2016Phase 2 study in CholestasisNCT02966834 · 147 enrolled · United States, Australia, Canada and more
- Jun 18, 2019Phase 1 study in CholestasisNCT03992014 · 6 enrolled · United Kingdom
- Aug 8, 2019Phase 1 study in CholestasisNCT04053023 · 19 enrolled · United Kingdom
- Nov 15, 2019Phase 3 study in CholestasisNCT04167358 · 242 enrolled · United States, Argentina, Brazil and more
- Jun 25, 2021Phase 3 study in PruritusNCT04950127 · 238 enrolled · Germany, United Kingdom
- Nov 12, 2021Phase 1 study in PruritusNCT05133830 · 52 enrolled · United States
- May 23, 2022Phase 1 study in PruritusNCT05393076 · 8 enrolled · United States
- Jun 22, 2022Phase 1 study in PruritusNCT05435170 · 23 enrolled · United Kingdom
- Sep 30, 2026Phase 3 study in PruritusNCT07860710 · 40 planned
Ahead
- Oct 23, 2028Primary completion: phase 3 study in PruritusNCT07860710
TargetBeta
SLC10A2 →read by rule
“Ileal bile acid transporter inhibitor”ChEMBL 37, by rule
Other programs on SLC10A2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| maralixibatrule | Mirum Pharmaceuticals | phase 4 | 21 |
Studies
All 14 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07860710Pruritus | 3 | Not yet recruiting | Oct 23, 2028 | 40 |
| NCT05435170Pruritus · United Kingdom | 1 | Completed | Oct 10, 2022 | 23 |
| NCT05393076Pruritus · United States | 1 | Completed | Dec 6, 2022 | 8 |
| NCT05133830Pruritus · United States | 1 | Completed | May 31, 2022 | 52 |
| NCT04950127Pruritus · Germany, United Kingdom | 3 | Completed | Oct 28, 2024 | 238 |
| NCT04167358Cholestasis · United States, Argentina, Brazil and more | 3 | Active, not recruiting | Sep 30, 2026 | 242 |
| NCT04053023Cholestasis · United Kingdom | 1 | Completed | Nov 25, 2019 | 19 |
| NCT03992014Cholestasis · United Kingdom | 1 | Completed | Aug 26, 2019 | 6 |
| NCT02966834Cholestasis · United States, Australia, Canada and more | 2 | Completed | Apr 15, 2020 | 147 |
| NCT02202161Diabetes Mellitus, Type 2 · United States | 2 | Completed | Jan 30, 2015 | 70 |
| NCT01929863Diabetes Mellitus, Type 2 · United States | 2 | Completed | Nov 1, 2013 | 16 |
| NCT01899703Cholestasis, Intrahepatic · United Kingdom | 2 | Completed | Oct 7, 2015 | 22 |
| NCT01607385Diabetes Mellitus, Type 2 · United States | 1 | Completed | Dec 3, 2012 | 56 |
| NCT01416324Diabetes Mellitus, Type 2 · United States | 1 | Completed | Sep 9, 2011 | 17 |
How it is read
Names in the registry
- “Linerixibat”, 5 entries
- “GSK2330672”, 5 entries
- “linerixibat”, 1 entry
- “GSK2330672 (linerixibat)”, 1 entry
- “Linerixibat tablet”, 1 entry
Conditions, from the studies’ own filings
- Pruritus, 5 studies
- Diabetes Mellitus, Type 2, 4 studies
- Liver Cirrhosis, Biliary, 3 studies
- Cholestasis, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.